Indian Journal of Animal Research

  • Chief EditorK.M.L. Pathak

  • Print ISSN 0367-6722

  • Online ISSN 0976-0555

  • NAAS Rating 6.50

  • SJR 0.263

  • Impact Factor 0.4 (2024)

Frequency :
Monthly (January, February, March, April, May, June, July, August, September, October, November and December)
Indexing Services :
Science Citation Index Expanded, BIOSIS Preview, ISI Citation Index, Biological Abstracts, Scopus, AGRICOLA, Google Scholar, CrossRef, CAB Abstracting Journals, Chemical Abstracts, Indian Science Abstracts, EBSCO Indexing Services, Index Copernicus

​​New Approach for Development of Inactivated RVF Virus Vaccine by using Chitosan and Aluminum Phosphate Nanoparticles as Adjuvant

Mohamed A. Hussein, Bahgat A. Abd El-Rhman, Kareem A. Eldin, Mohamed Fouad Mansour
Background: Rift Valley fever (RVF) is a zoonotic disease that causing great economic losses in animals wealth. Vaccination with RFV vaccines are an important factor for controlling the disease. This study was conducted to investigate the immunological effect of chitosan and aluminum phosphate nanoparticles as adjuvants. 
Methods: Evaluating the cellular and humoral immune responses in sheep vaccinated with the prepared RVF vaccines.  
Result: The prepared vaccines were sterile and safe. The potent lymphocytic cell proliferation of cell-mediated immune response was early increased with significant level from 1st day post-inoculation and reached the peak at the 5th, 7th and 10th days post-inoculation in groups vaccinated with Chitosan nanoparticles RVF vaccine, aluminum phosphate nanoparticles vaccine and aluminum hydroxide RVF vaccine respectively. The results of cytokines (IL-12, TNF-α mRNA expression level and IFN-γ) were consistent with the results of cell proliferation. Neutralizing antibody it was increased significantly from the 2nd week post-inoculation and reached the peak at 5th, 4th and 3rd months in groups inoculated with Chitosan nanoparticles RVF vaccine, aluminum phosphate nanoparticles vaccine and aluminum hydroxide RVF vaccine respectively. ELISA results correlated with that obtained by SNT. Our study showed that both nanoparticles RVF vaccines induced rapid immunological response with long duration of immunity. 

  1. Alsaid, S.A., Abul Magd, D.M., Atwa, M.H. and Soliman, S.M. (2020). Evaluation of the cellular and humeral immune response of sheep vaccinated with inactivated Rift valley fever vaccine adjuvant with montanide gel 01tm. Journal of Applied Veterinary Sciences. 5: 22-34.

  2. Devamani, R. and Alagar, M. (2012). Synthesis and characterization of aluminum phosphate nanoparticles. International Journal of Applied Science and Engineering Research 1.6: 769-775.

  3. Dina, M.A. (2015). Vaccination against Rift Valley Fever Disease. Degree of Doctor of Philosophy in Veterinary Sciences Infectious Diseases, Benha University, Faculty of Veterinary Medicine, Moshtohor, Zagazig University.                                             

  4. Eman, M.S. (1995). Studies on Rift Valley Fever vaccine inactivated with Binary. Ph. D. Thesis, Microbiology, Fac. of Vet. Med., Cairo Univ.

  5. EL Manzalawy M.A., Taradi, A.S. and Hassan, K.E.Z. (2012). The effect of chitosan on sheep vaccinated with in activated RVF vaccine. Zagzig Veterinary Journal. 40: 93-99.

  6. Faburay, B., LaBeaud, A.D., McVey, D.S., Wilson, W.C. and Rich, J.A. (2017). Current status of rift valley fever vaccine development. Vaccines. 5: 29-32.

  7. Gihan, K.M. Khodeir, M.H. and Khirate Abdel Megid. (1993). Studies on liver function in cattle vaccinated with Rinderpest and Rift Valley vaccines.

  8. Ibrahim, A.M. (2002). Improvement and evaluation of inactivated Rift valley fever vaccine. Ph.D. Thesis, Infectious Diseases, Faculty Veterinary Medicine, Moshtohor, Zagazig University.

  9. IIIum, L. (1998). Chitosan and its use as a pharmaceutical excipient. Pharmaceutical Development and Technology Research. 15: 1326-1331.

  10. Hammad, M.Y. (2015). Some studies on Rift Valley Fever vaccine, PhD. Thesis, Faculty of Veterinary Medicine, Benha University.

  11. Hilde, V., Margarita, E.B., Martin, H., Greert, J.W., Peter, S., Wim, J., Gideon, K. and Bernard, M. (2019). Stabilized aluminum phosphate nanoparticles used as vaccine adjuvant  colloids and surfaces B: Bio interfaces. 181: 648-656.

  12. Lee, L.F. (1984). Proliferative response of chicken B and T lymphocyte to mitogen. Veterinary Medecine. 15: 44-52.

  13. Look, M., Bandyopadhyay, A., Blum, J.S. and Fahmy, T.M. (2009). Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv. Drug. Deliv. Rev. 62: 378-393.

  14. Meadus, G.F., Gibbs, P.H. and Peters, C.J. (2003). Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials. Vaccine. 4: 179-84.   

  15. Naggar, H.M.E., Madkour, M.S. and Hussein, H.A. (2017). Preparation of mucosal nanoparticles and polymer-based inactivated vaccine for Newcastle disease and H9N2 AI viruses. Veterinary World. 10: 187-193.

  16. OIE, (2016). Terrestrial Manual 2016. Chapter 2. 1. 18 Rift Valley fever. Paris, France: World Organization for Animal Health. 

  17. Pan, L., Zhang, Z., Lv, J., Zhou, P., Hu, W., Fang, Y., Chen, H., Liu, X., Shao, J., Zhao, F., Ding, Y., Lin, T., Chang, H., Zhang, J. and Wang, Y. (2002). Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles. International Journal of Nano medicine. 9: 5603-5618.

  18. Randall and Harison, V.R. (1964). Immunization against Rift valley fever virus. Studies on the immunogenicity of lyophilized formalin inactivated vaccine. Journal Immunology. 93: 293.

  19. Reed, L. J. and Munch, H. (1938). A simple method for estimating 50 per cent end point. American Journal of Hygiene. 27: 493-497. 

  20. Scudiero, D.A., Shoemaker, R.H., Paull, K.D., Monks, A., Tierney, S., Nofziger, T.H., Currens, M.J., Seniff, D. and Boyd, M.R. (1988). Evaluation of soluble tetrazolium / Formazan Assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Research. 48: 4827-4833.

  21. Ulanova, M., Alhazmi, A. and Choi, J. (2001). The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin- 4- dependent mechanism. Infect Immunology. 1151-1159.

  22. Vander Lubben, I.M., Verhoef, J.C., Borchard, G. and Junginger, H.E. (2001). Chitosan and its derivative sin mucosal drug and vaccine delivery. European Journal Pharmaceutical  Science. 14: 201-207.                                                                                                         

  23. Voller, A. Bidwell, D. and Bartlett, A. (1976). Micro plate enzyme immunoassay for the immune dagnosis of virus infection. Am. Soc. for Micro., 506-512. 

  24. Walker, J.S. (1975). Rift Valley Fever Foreign Animal Disease: Their Prevention, Diagnosis and Control. Committee of foreign animal disease of the United States. Animal Health Assoc.: 209-221.

Editorial Board

View all (0)